标题
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
作者
关键词
-
出版物
Cancers
Volume 13, Issue 9, Pages 2018
出版商
MDPI AG
发表日期
2021-04-22
DOI
10.3390/cancers13092018
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
- (2021) Almudena García-Ortiz et al. Cancers
- Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
- (2021) Leona Yamamoto et al. Frontiers in Oncology
- Metabolic Reprogramming Induces Immune Cell Dysfunction in the Tumor Microenvironment of Multiple Myeloma
- (2021) Shaojie Wu et al. Frontiers in Oncology
- Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?
- (2021) Anne Marit Sponaas et al. Frontiers in Immunology
- Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug
- (2021) Fatih M. Uckun et al. Frontiers in Pharmacology
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
- (2020) Joshua D. Hansen et al. JOURNAL OF MEDICINAL CHEMISTRY
- B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
- (2020) Nina Shah et al. LEUKEMIA
- Multiple Myeloma: Available Therapies and Causes of Drug Resistance
- (2020) Vanessa Pinto et al. Cancers
- Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma
- (2020) Stefania Raimondo et al. Cancers
- Immunotherapy in Multiple Myeloma
- (2020) Cinnie Yentia Soekojo et al. Cells
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
- (2020) Jumpei Teramachi et al. HAEMATOLOGICA
- Immunotherapy of multiple myeloma
- (2020) Simone A. Minnie et al. JOURNAL OF CLINICAL INVESTIGATION
- Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
- (2020) Nandakumar Packiriswamy et al. LEUKEMIA
- Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
- (2020) Deming Feng et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions
- (2020) Chiara Caraccio et al. Frontiers in Immunology
- Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
- (2020) Maria-Victoria Mateos et al. Lancet Haematology
- Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
- (2020) Lisa C. Holthof et al. Cancers
- Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
- (2020) Ewelina Grywalska et al. Cells
- Cancer Cells Don’t Live Alone: Metabolic Communication within Tumor Microenvironments
- (2020) Fuming Li et al. DEVELOPMENTAL CELL
- Multiple myeloma: the (r)evolution of current therapy and a glance into future
- (2020) Annamaria Gulla et al. HAEMATOLOGICA
- Multiple Myeloma-Derived Extracellular Vesicles Induce Osteoclastogenesis through the Activation of the XBP1/IRE1α Axis
- (2020) Lavinia Raimondi et al. Cancers
- CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
- (2020) Luis Gerardo Rodríguez-Lobato et al. Frontiers in Oncology
- Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
- (2020) Smith Giri et al. JAMA Oncology
- Daratumumab-based Induction Therapy for Multiple Myeloma: A Systematic Review and Meta-analysis
- (2020) Lip Leong Chong et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance
- (2019) Ayako Nagao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- Anti-BCMA antibodies in the future management of multiple myeloma
- (2019) Maria Gavriatopoulou et al. Expert Review of Anticancer Therapy
- Oprozomib, pomalidomide, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
- (2019) Jatin Shah et al. Clinical Lymphoma Myeloma & Leukemia
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
- (2019) Frans V. Suurs et al. PHARMACOLOGY & THERAPEUTICS
- Current status of autologous stem cell transplantation for multiple myeloma
- (2019) Rama Al Hamed et al. Blood Cancer Journal
- Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
- (2019) Maria C. Ochoa et al. OncoImmunology
- Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
- (2019) Haimeng Yan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation
- (2019) M. Frenquelli et al. LEUKEMIA
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
- (2019) Sabrina Trudel et al. OncoTargets and Therapy
- The future of checkpoint inhibition in multiple myeloma?
- (2019) Caitlin Costello Lancet Haematology
- Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
- (2019) Alfonso Serrano-del Valle et al. Frontiers in Cell and Developmental Biology
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- The emerging role of exosomes in multiple myeloma
- (2019) Milad Moloudizargari et al. BLOOD REVIEWS
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression
- (2019) Shunye Wang et al. Translational Oncology
- Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
- (2019) Alexander M. Lesokhin et al. Cancer Immunology Research
- Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
- (2019) Chad C. Bjorklund et al. LEUKEMIA
- Recurrent or Refractory High-Grade Gliomas Treated by Convection-Enhanced Delivery of a TGFβ2-Targeting RNA Therapeutic: A Post-Hoc Analysis with Long-Term Follow-Up
- (2019) Fatih M. Uckun et al. Cancers
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration
- (2019) Christian M. Schürch et al. VIRCHOWS ARCHIV
- Immunotherapy for Multiple Myeloma
- (2019) Hideto Tamura et al. Cancers
- Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
- (2018) Kyohei Nakamura et al. CANCER CELL
- The Science and Translation of Lactate Shuttle Theory
- (2018) George A. Brooks Cell Metabolism
- TGF-β Inhibition and Immunotherapy: Checkmate
- (2018) Karuna Ganesh et al. IMMUNITY
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
- (2018) De-Xiu Bu et al. Oncotarget
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
- (2018) Remy Thomas et al. Frontiers in Immunology
- Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
- (2018) Meletios A. Dimopoulos et al. CANCER
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
- (2018) Shaji K. Kumar et al. BRITISH JOURNAL OF HAEMATOLOGY
- The challenges of checkpoint inhibition in the treatment of multiple myeloma
- (2018) Barry Paul et al. CELLULAR IMMUNOLOGY
- High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
- (2018) Homer C. Adams et al. CYTOMETRY PART A
- Molecular Repolarisation of Tumour-Associated Macrophages
- (2018) Floris van Dalen et al. MOLECULES
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
- (2018) Kerry S. Campbell et al. Frontiers in Immunology
- Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
- (2018) Sara Tognarelli et al. Frontiers in Immunology
- Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Tomas Jelinek et al. Frontiers in Immunology
- Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma
- (2018) Fatih M. Uckun et al. EBioMedicine
- Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma
- (2017) Q Wang et al. LEUKEMIA
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Lymphocyte-activation gene-3, an important immune checkpoint in cancer
- (2016) Yayi He et al. CANCER SCIENCE
- Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
- (2016) Jinheng Wang et al. JOURNAL OF PATHOLOGY
- From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration
- (2015) Joschka Lorenz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
- (2015) Enrica Borsi et al. Oncotarget
- Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
- (2014) Masanori Matsumoto et al. IMMUNITY
- Targeting the bone marrow microenvironment in multiple myeloma
- (2014) Yawara Kawano et al. IMMUNOLOGICAL REVIEWS
- Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
- (2013) F. M. Uckun et al. BLOOD
- Targeting lactate metabolism for cancer therapeutics
- (2013) Joanne R. Doherty et al. JOURNAL OF CLINICAL INVESTIGATION
- Macrophages in multiple myeloma: emerging concepts and therapeutic implications
- (2013) Fotis Asimakopoulos et al. LEUKEMIA & LYMPHOMA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now